Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy Journal Article

  


Authors: Sabbatini, P.; Mooney, D.; Iasonos, A.; Thaler, H.; Aghajanian, C.; Hensley, M.; Konner, J.; Spriggs, D.; Abu-Rustum, N. R.; Dupont, J.
Article Title: Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy
Abstract: The objective of this study was to analyze retrospective populations with recurrent ovarian cancer to assess differences in CA-125 patterns during chemotherapy. The populations included all patients treated between January 1994 and January 2004, who received liposomal doxorubicin and topotecan, and all patients treated between July 1997 and June 2001, who received carboplatin. Prognostic variables were abstracted from the medical records. Eighty-nine patients received liposomal doxorubicin and topotecan therapy and 21 received carboplatin; of these, 59 (liposomal doxorubicin), 60 (topotecan), and 17 (carboplatin) patients had evaluable CA-125 patterns. Patients given liposomal doxorubicin were more likely to have received only one or two cycles of therapy (37/89 [42%]) than patients receiving either carboplatin (5/21 [24%]) or topotecan (20/89[22%]). In cycle 1, CA-125 increases in patients were carboplatin, 4/17 (24%); liposomal doxorubicin, 41/59 (69%); and topotecan, 11/60 (18%). In cycle 2, CA-125 increases were carboplatin, 2/16 (13%); liposomal doxorubicin, 19/37 (51%); and topotecan, 9/50 (18%). In cycle 3, CA-125 increases were carboplatin, 0/12 (0%); liposomal doxorubicin, 7/23 (30%); and topotecan, 6/38 (16%). Of patients having any CA-125 decrease and given two or more cycles, fewer declines were seen in those given liposomal doxorubicin precycle 2 (18/35[51%]) than in those given carboplatin (13/16[81%]) or topotecan (49/56[88%]). The most prominent delay in CA-125 decline was in patients given liposomal doxorubicin compared with those given topotecan or carboplatin. In the entire population, only 3 of 107 (2.8%) patients demonstrated first CA-125 decline precycle 4. Discontinuation of therapy solely on the basis of early CA-125 increase (precycle 3), particularly with liposomal doxorubicin chemotherapy, may exclude some patients who will benefit from continued therapy. © 2007, IGCS and ESGO.
Keywords: adult; cancer chemotherapy; controlled study; aged; aged, 80 and over; middle aged; retrospective studies; major clinical study; cancer recurrence; cisplatin; doxorubicin; topotecan; ovarian cancer; ovarian neoplasms; carboplatin; multiple cycle treatment; ovary cancer; neoplasm recurrence, local; bone marrow suppression; antineoplastic combined chemotherapy protocols; retrospective study; time factors; rash; gene expression regulation, neoplastic; medical record; carcinoma; ca 125 antigen; ca-125 antigen; time series analysis; recurrent; hypersensitivity; ca-125 response
Journal Title: International Journal of Gynecological Cancer
Volume: 17
Issue: 3
ISSN: 1048-891X
Publisher: Lippincott Williams & Wilkins  
Date Published: 2007-05-01
Start Page: 589
End Page: 594
Language: English
DOI: 10.1111/j.1525-1438.2007.00823.x
PUBMED: 17300679
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-34248371170&partnerID=40&md5=7d981b194f57450ad07717ce41f73476
Notes: --- - "Cited By (since 1996): 6" - "Export Date: 17 November 2011" - "CODEN: IJGCE" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jakob Dupont
    65 Dupont
  2. Jason Konner
    155 Konner
  3. Nadeem Abu-Rustum
    888 Abu-Rustum
  4. Paul J Sabbatini
    262 Sabbatini
  5. Alexia Elia Iasonos
    362 Iasonos
  6. Martee L Hensley
    289 Hensley
  7. Carol A Aghajanian
    607 Aghajanian
  8. David R Spriggs
    325 Spriggs
  9. Howard T Thaler
    245 Thaler
Related MSK Work